GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

US11352405B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Aimo Kannt · Dreieich, DE
• Maximilian BIELOHUBY · Frankfurt am Main, DE
• Ralf Elvert · Frankfurt am Main, DE
• Michael Wagner · Frankfurt am Main, DE
• Martin Bossart · Frankfurt am Main, DE
• Torsten Haack · Frankfurt am Main, DE
• Stephanie Keil · Frankfurt am Main, DE
• Werner Seiz · Frankfurt am Main, DE

Key dates

• Filing date: Aug 8, 2018
• Grant date: Jun 7, 2022
• Expiry date: Aug 8, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.